Just a few months after Tysabri was approved for MS treatment, two patients developed progressive multifocal leukoencephalopathy (PML), a fatal or seriously debilitating disease. In his second talk, Yednock describes the response of medical and regulatory groups and researchers to this discovery and its impact on the treatment of MS patients with Natalizumab/Tysabri.
View the full talk with additional resources on our website
Discovery and Development of Tysabri (Natalizumab) for the Treatment of Multiple Sclerosis
Ted Yednock relates the discovery and development, over 15 years, of the drug Tysabri (Natalizumab), an 4 integrin antibody, as a treatment for multiple sclerosis. (Talk recorded in January 2014)
- Part 1: Immune Cell Migration to the CNSAudience:
- Researcher
Duration: 34:53 - Part 2: Response to the Emergence of Progressive Multifocal LeukoencephalopathyAudience:
- Researcher
Duration: 29:26